PTC-174

PTC-174 is a selective positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors containing GluN2C or GluN2D subunits. It was originally synthesized by Chinglu Pharmaceutical Research and developed as a preclinical tool compound by Cadent Therapeutics (formerly Mnemosyne Pharmaceuticals, later acquired by Novartis). PTC-174 potentiates NMDA receptor-mediated responses by increasing the potencies of co-agonists glutamate and glycine, and prolonging the decay of excitatory postsynaptic currents (EPSCs). It is primarily used as a research-use-only reagent to investigate the physiology and pharmacology of GluN2C- and GluN2D-containing NMDA receptors, particularly in the context of schizophrenia, cognitive deficits, and basal ganglia circuitry.

Other names

8-(6-(tert-butyl)pyridin-3-yl)-6-oxo-3,4-dihydro-2H,6H-pyrimido[2,1-b][1,3]thiazine-7-carbonitrile